Differential neuroimaging indices in prefrontal white matter in prenatal alcohol-associated ADHD versus idiopathic ADHD.
Adolescent
Attention Deficit Disorder with Hyperactivity
/ diagnostic imaging
Child
Diffusion Tensor Imaging
Female
Fetal Alcohol Spectrum Disorders
/ diagnostic imaging
Humans
Magnetic Resonance Imaging
Male
Prefrontal Cortex
/ diagnostic imaging
Pregnancy
Prenatal Exposure Delayed Effects
/ diagnostic imaging
White Matter
/ diagnostic imaging
anterior corona radiata
attention deficit hyperactivity disorder
diffusion tensor imaging
fetal alcohol spectrum disorder
magnetic resonance spectroscopy
Journal
Birth defects research
ISSN: 2472-1727
Titre abrégé: Birth Defects Res
Pays: United States
ID NLM: 101701004
Informations de publication
Date de publication:
15 07 2019
15 07 2019
Historique:
received:
04
09
2018
revised:
08
12
2018
accepted:
03
01
2019
pubmed:
30
1
2019
medline:
8
5
2020
entrez:
30
1
2019
Statut:
ppublish
Résumé
Attention deficit-hyperactivity disorder (ADHD) is common in fetal alcohol spectrum disorders (FASD) but also in patients without prenatal alcohol exposure (PAE). Many patients diagnosed with idiopathic ADHD may actually have ADHD and covert PAE, a treatment-relevant distinction. We compared proton magnetic resonance spectroscopic imaging (MRSI; N = 44) and diffusion tensor imaging (DTI; N = 46) of the anterior corona radiata (ACR)-a key fiber tract in models of ADHD-at 1.5 T in children with ADHD with PAE (ADHD+PAE), children with ADHD without PAE (ADHD-PAE), children without ADHD with PAE (non-ADHD+PAE), and children with neither ADHD nor PAE (non-ADHD-PAE, i.e., typically developing controls). Levels of choline-compounds (Cho) were the main MRSI endpoint, given interest in dietary choline for FASD; the main DTI endpoint was fractional anisotropy (FA), as ACR FA may reflect ADHD-relevant executive control functions. For ACR Cho, there was an ADHD-by-PAE interaction (p = 0.038) whereby ACR Cho was 26.7% lower in ADHD+PAE than in ADHD-PAE children (p < 0.0005), but there was no significant ACR Cho difference between non-ADHD+PAE and non-ADHD-PAE children. Voxelwise false-discovery rate (FDR)-corrected analysis of DTI revealed significantly (q ≤ 0.0101-0.05) lower FA in ACR for subjects with PAE (ADHD+PAE or non-ADHD+PAE) than for subjects without PAE (ADHD-PAE or non-ADHD-PAE). There was no significant effect of ADHD on FA. Thus, in overlapping samples, effects of PAE on Cho and FA were observed in the same white-matter tract. These findings point to tract focal, white-matter pathology possibly specific for ADHD+PAE subjects. Low Cho may derive from abnormal choline metabolism; low FA suggests suboptimal white-matter integrity in PAE. More advanced MRSI and DTI-and neurocognitive assessments-may better distinguish ADHD+PAE from ADHD-PAE, helping identify covert cases of FASD.
Sections du résumé
BACKGROUND
Attention deficit-hyperactivity disorder (ADHD) is common in fetal alcohol spectrum disorders (FASD) but also in patients without prenatal alcohol exposure (PAE). Many patients diagnosed with idiopathic ADHD may actually have ADHD and covert PAE, a treatment-relevant distinction.
METHODS
We compared proton magnetic resonance spectroscopic imaging (MRSI; N = 44) and diffusion tensor imaging (DTI; N = 46) of the anterior corona radiata (ACR)-a key fiber tract in models of ADHD-at 1.5 T in children with ADHD with PAE (ADHD+PAE), children with ADHD without PAE (ADHD-PAE), children without ADHD with PAE (non-ADHD+PAE), and children with neither ADHD nor PAE (non-ADHD-PAE, i.e., typically developing controls). Levels of choline-compounds (Cho) were the main MRSI endpoint, given interest in dietary choline for FASD; the main DTI endpoint was fractional anisotropy (FA), as ACR FA may reflect ADHD-relevant executive control functions.
RESULTS
For ACR Cho, there was an ADHD-by-PAE interaction (p = 0.038) whereby ACR Cho was 26.7% lower in ADHD+PAE than in ADHD-PAE children (p < 0.0005), but there was no significant ACR Cho difference between non-ADHD+PAE and non-ADHD-PAE children. Voxelwise false-discovery rate (FDR)-corrected analysis of DTI revealed significantly (q ≤ 0.0101-0.05) lower FA in ACR for subjects with PAE (ADHD+PAE or non-ADHD+PAE) than for subjects without PAE (ADHD-PAE or non-ADHD-PAE). There was no significant effect of ADHD on FA. Thus, in overlapping samples, effects of PAE on Cho and FA were observed in the same white-matter tract.
CONCLUSIONS
These findings point to tract focal, white-matter pathology possibly specific for ADHD+PAE subjects. Low Cho may derive from abnormal choline metabolism; low FA suggests suboptimal white-matter integrity in PAE. More advanced MRSI and DTI-and neurocognitive assessments-may better distinguish ADHD+PAE from ADHD-PAE, helping identify covert cases of FASD.
Identifiants
pubmed: 30694611
doi: 10.1002/bdr2.1460
pmc: PMC6650301
mid: NIHMS1013290
doi:
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
797-811Subventions
Organisme : NIMH NIH HHS
ID : R01 MH081864
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA025066
Pays : United States
Organisme : NCRR NIH HHS
ID : P41 RR013642
Pays : United States
Organisme : NIMH NIH HHS
ID : P01 MH063357
Pays : United States
Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Neuroimage. 2004;23 Suppl 1:S208-19
pubmed: 15501092
Neuroimage. 2008 Apr 1;40(2):570-582
pubmed: 18255316
Neurosci Biobehav Rev. 2012 Apr;36(4):1093-106
pubmed: 22305957
Psychiatry Res. 2010 Mar 30;181(3):193-8
pubmed: 20153608
Neurotherapeutics. 2007 Jul;4(3):316-29
pubmed: 17599699
Brain Res Brain Res Rev. 2004 Mar;44(2-3):83-102
pubmed: 15003387
J Psychiatr Res. 2007 Dec;41(11):934-41
pubmed: 17303167
Alcohol Clin Exp Res. 1997 Feb;21(1):150-61
pubmed: 9046388
J Child Adolesc Psychopharmacol. 1998;8(1):39-48
pubmed: 9639078
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jan 10;36(1):161-8
pubmed: 21983143
Neurochem Int. 1985;7(2):369-72
pubmed: 20492936
Clin Neuropsychol. 2009 Apr;23(3):428-45
pubmed: 18815943
Metab Brain Dis. 2014 Jun;29(2):323-32
pubmed: 24488204
Life Sci. 1976 Oct 1;19(7):949-61
pubmed: 792606
Neurology. 1977 Aug;27(8):783-90
pubmed: 560649
Pediatrics. 2014 Nov;134(5):855-66
pubmed: 25349310
Pediatrics. 1994 Apr;93(4):594-601
pubmed: 8134214
J Am Acad Child Adolesc Psychiatry. 1997 Aug;36(8):1065-79
pubmed: 9256586
Behav Neurosci. 2006 Apr;120(2):482-7
pubmed: 16719711
Alcohol Clin Exp Res. 2006 Oct;30(10):1799-806
pubmed: 17010147
Alcohol Clin Exp Res. 2011 May;35(5):849-61
pubmed: 21303384
Alcohol Clin Exp Res. 2008 Oct;32(10):1697-707
pubmed: 18631322
Neuropsychol Rev. 2011 Jun;21(2):133-47
pubmed: 21347880
J Am Acad Child Adolesc Psychiatry. 2000 Jan;39(1):28-38
pubmed: 10638065
Neurosci Biobehav Rev. 2016 Sep;68:838-847
pubmed: 27450582
Metab Brain Dis. 2016 Oct;31(5):1105-12
pubmed: 27311608
J Psychiatr Res. 2013 Apr;47(4):494-504
pubmed: 23290560
Neurosci Lett. 2001 Nov 23;315(1-2):45-8
pubmed: 11711211
Schizophr Res. 2012 Jul;138(2-3):150-6
pubmed: 22405729
NMR Biomed. 2001 Jun;14(4):260-4
pubmed: 11410943
Hum Brain Mapp. 2013 Apr;34(4):796-813
pubmed: 22110013
Neuropsychiatr Dis Treat. 2010 Sep 07;6:509-15
pubmed: 20856914
Biophys J. 1994 Jan;66(1):259-67
pubmed: 8130344
Scan Electron Microsc. 1982;(Pt 1):309-22
pubmed: 7167750
Neurotoxicol Teratol. 2004 Jan-Feb;26(1):35-45
pubmed: 15001212
J Neurodev Disord. 2015;7(1):10
pubmed: 25750685
J Psychiatr Res. 2013 Apr;47(4):505-12
pubmed: 23273650
Alcohol Res Health. 2011;34(1):51-5
pubmed: 23580041
Alcohol Clin Exp Res. 2013 Mar;37(3):517-28
pubmed: 22974253
Acta Psychiatr Scand. 2000 Dec;102(6):401-13
pubmed: 11142428
Appl Neuropsychol Child. 2015;4(4):230-6
pubmed: 25318015
JAMA. 2018 Feb 6;319(5):474-482
pubmed: 29411031
Ciba Found Symp. 1984;105:124-41
pubmed: 6563984
Hum Brain Mapp. 2016 Aug;37(8):2943-58
pubmed: 27219850
Neuroimage. 2002 Dec;17(4):1807-19
pubmed: 12498754
Hum Brain Mapp. 2009 Oct;30(10):3265-74
pubmed: 19278010
Alcohol Clin Exp Res. 2008 Oct;32(10):1732-40
pubmed: 18671811
Child Psychiatry Hum Dev. 2016 Apr;47(2):335-46
pubmed: 26202432
World J Biol Psychiatry. 2009;10(4 Pt 2):355-65
pubmed: 18609427
Arq Neuropsiquiatr. 2009 Jun;67(2A):254-61
pubmed: 19547818
Alcohol Clin Exp Res. 2005 Aug;29(8):1359-67
pubmed: 16131842
PLoS One. 2013 Nov 04;8(11):e78831
pubmed: 24223852
Neuroimage. 2006 Jul 15;31(4):1487-505
pubmed: 16624579
Alcohol Clin Exp Res. 2009 Oct;33(10):1825-35
pubmed: 19645729
J Comput Assist Tomogr. 1998 Jan-Feb;22(1):153-65
pubmed: 9448780
Front Neuroanat. 2010 Feb 22;4:2
pubmed: 20204143
Magn Reson Med. 2003 Nov;50(5):1077-88
pubmed: 14587019
Biol Psychiatry. 2009 Jan 1;65(1):84-8
pubmed: 18842255
Brain. 2007 Jul;130(Pt 7):1767-76
pubmed: 17522104
Alcohol. 2017 May;60:159-167
pubmed: 28433422
Prog Neuropsychopharmacol Biol Psychiatry. 2001 Jan;25(1):5-26
pubmed: 11263758
Alcohol Clin Exp Res. 2014 May;38(5):1330-8
pubmed: 24655149
Alcohol Clin Exp Res. 2013 May;37(5):748-56
pubmed: 23240997
Psychopharmacology (Berl). 2010 Mar;209(1):13-24
pubmed: 20101394
Magn Reson Imaging. 2009 Jun;27(5):681-90
pubmed: 19027254
J Neural Transm (Vienna). 2009 May;116(5):623-9
pubmed: 19399368
Magn Reson Imaging. 2009 Jul;27(6):760-78
pubmed: 19342189
Magn Reson Med. 1990 Jan;13(1):90-102
pubmed: 2319938
Neurotoxicol Teratol. 2009 Sep-Oct;31(5):303-11
pubmed: 19616089
Brain Res. 1989 Apr 10;484(1-2):217-27
pubmed: 2713682
J Cogn Neurosci. 2002 Apr 1;14(3):340-7
pubmed: 11970796
Int J Dev Neurosci. 1990;8(5):507-22
pubmed: 1980786
Neurotoxicol Teratol. 1995 Sep-Oct;17(5):523-30
pubmed: 8551998
Dev Disabil Res Rev. 2009;15(3):225-34
pubmed: 19731386
J Mol Neurosci. 2008;34(1):51-61
pubmed: 18157658
J Dev Behav Pediatr. 2017 May;38(4):283-291
pubmed: 28460370
Neurotoxicol Teratol. 2006 Sep-Oct;28(5):597-606
pubmed: 16996247
Semin Clin Neuropsychiatry. 2000 Jul;5(3):177-90
pubmed: 11291013
Brain. 2008 Dec;131(Pt 12):3209-21
pubmed: 18952679
Alcohol Clin Exp Res. 2009 Mar;33(3):514-21
pubmed: 19120066
J Neurosci. 2008 Feb 6;28(6):1313-9
pubmed: 18256251
Anat Rec (Hoboken). 2009 Dec;292(12):1922-39
pubmed: 19943346
Neurotoxicol Teratol. 2000 Sep-Oct;22(5):703-11
pubmed: 11106863
Alcohol Clin Exp Res. 2006 Dec;30(12):2097-104
pubmed: 17117975
J Neuroophthalmol. 2005 Sep;25(3):217-26
pubmed: 16148633
J Psychiatr Res. 2008 Jun;42(7):587-95
pubmed: 17698080
Psychopharmacology (Berl). 2012 May;221(2):285-95
pubmed: 22215225
Dev Med Child Neurol. 1999 Oct;41(10):652-9
pubmed: 10587040
Nutr Res. 2013 Nov;33(11):897-904
pubmed: 24176229
Biol Psychiatry. 2009 Apr 1;65(7):586-93
pubmed: 19027102
Neuroreport. 2001 Mar 5;12(3):515-23
pubmed: 11234756
J Neuropsychiatry Clin Neurosci. 2004 Winter;16(1):63-9
pubmed: 14990761
Alcohol Clin Exp Res. 1998 Apr;22(2):279-94
pubmed: 9581631
Hippocampus. 2012 Mar;22(3):619-30
pubmed: 21542051
Neuroreport. 2008 Nov 19;19(17):1705-8
pubmed: 18841089
Alcohol Res Health. 2001;25(3):199-203
pubmed: 11810958
Behav Neurosci. 2007 Feb;121(1):120-30
pubmed: 17324056
Can J Psychiatry. 2002 May;47(4):349-54
pubmed: 12025433
Neuroimage. 2001 May;13(5):856-76
pubmed: 11304082
PLoS One. 2012;7(7):e38786
pubmed: 22848344
Am J Anat. 1983 Mar;166(3):257-69
pubmed: 6846205
Environ Health Perspect. 1999 Feb;107 Suppl 1:65-9
pubmed: 10229708
J Am Acad Child Adolesc Psychiatry. 2013 Apr;52(4):431-440.e4
pubmed: 23582873
Am J Clin Nutr. 2015 Nov;102(5):1113-25
pubmed: 26447156
Mol Neurobiol. 2011 Oct;44(2):185-91
pubmed: 21259123
Schizophr Res. 2011 Dec;133(1-3):82-90
pubmed: 21872444
J Child Adolesc Psychopharmacol. 2008 Aug;18(4):365-71
pubmed: 18759646
Psychiatry Res. 2010 Sep 30;183(3):230-6
pubmed: 20702071